| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Revenue | $175.1M | +216.9% |
| Cost of Revenue | $22.6M | +183.4% |
| Gross Profit | $152.5M | +222.6% |
| R&D Expense | $32.8M | -3.8% |
| SG&A Expense | $279.7M | -3.8% |
| Operating Income | -$160.0M | +42.3% |
| Pre-tax Income | -$221.2M | +33.8% |
| Income Tax | $0 | — |
| Net Income | -$221.2M |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $130.0M | -56.3% |
| Accounts Receivable | $78.1M | +101.4% |
| Inventory | $5.5M | +72.0% |
| Current Assets | $229.0M | -36.4% |
| Total Assets | $259.1M | -31.5% |
| Current Liabilities | $132.0M | +54.0% |
| Long-term Debt | $209.1M | +3.8% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$166.8M | +37.5% |
| Capital Expenditures | $229K | +69.6% |
| Investing Cash Flow | -$229K | -69.6% |
| Financing Cash Flow | -$288K | -100.2% |
| Free Cash Flow | -$167.0M | +37.4% |
| +33.8% |
| EPS (Basic) | -$3.03 | +42.7% |
| EPS (Diluted) | -$3.03 | +42.7% |
| Total Liabilities |
| $697.3M |
| +10.4% |
| Stockholders' Equity | -$438.2M | -72.8% |